Whereas, MECOM has been found to function as both oncogene and tumor suppressor gene (TSG) in some solid tumors (13), which was observed to be overexpressed in colon and breast cancer specimens and correlated with worse outcomes (31, 32), by contrast, the favorable prognosis of ovarian cancer patients were identified to be associated with amplification of MECOM gene (33). This evidence concerns the gene MECOM and breast carcinoma.